To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
A phase 2 trial of Osimertinib, Carboplatin, Cisplatin and Pemetrexed in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Overview
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations is a phase 2 interventional study registered as NCT06194448 by AstraZeneca, with 76 participants enrolled, started 2024-04-21 and due to reach its primary completion in 2026-07-07. Interventions recorded: Osimertinib, Cisplatin or Carboplatin; Pemetrexed or Paclitaxel and Radiation.
Similar pages
not linked directly; found by shared links- TrialSavolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Shares Osimertinib, Pemetrexed, Cisplatin, AstraZeneca and the tag pipeline.
- TrialOsimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Pemetrexed, Cisplatin, AstraZeneca, Carboplatin and the tag pipeline.
- TrialA Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Shares Osimertinib, Pemetrexed, Cisplatin, Carboplatin and the tag pipeline.
- TrialA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Shares Pemetrexed, Cisplatin, AstraZeneca, Carboplatin and the tag pipeline.